Clik here to view.
EOS imaging And Fosun Pharmaceutical AG Enter into an Agreement for a...
PARIS Regulatory News: EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI), the pioneer of orthopedic medical imaging 2D / 3D, today announced that it entered into a binding agreement with...
View ArticleClik here to view.
PHC Holdings Corporation: Introducing the New -85 °C Ultra-Low Temperature...
TOKYO PHC Corporation (hereafter PHC), a wholly-owned subsidiary of PHC Holdings Corporation (headquarters: Tokyo, Japan) has introduced a new -85°C ultra-low temperature freezer VIP ECO series*1...
View ArticleClik here to view.
ＰＨＣホールディングス株式会社: 省エネルギーと地球環境保護を追求した －８５℃超低温フリーザー「VIP ECO」シリーズを販売開始
東京 （ビジネスワイヤ） — ＰＨＣホールディングス株式会社（本社：東京都港区）の１００％子会社である、ＰＨＣ株式会社（以下「ＰＨＣ」）は、このたび、製薬企業および研究・医療機関向けに、自然冷媒（＊１）を使用しインバーター制御コンプレッサーを搭載した－８５℃超低温フリーザー「VIP...
View ArticleClik here to view.
Cullgen Announces Expanded Scientific Advisory Board
DELAWARE Cullgen Inc, (“Cullgen” or the “Company), a drug discovery company focused on development of drug candidates using uSMITE™ (ubiquitin mediated small molecule induced target elimination),...
View ArticleClik here to view.
Samsung BioLogics Streamlines Quality Document Management Globally With Veeva...
PLEASANTON, Calif. Veeva Systems (NYSE:VEEV) today announced that Samsung BioLogics selected Veeva Vault QualityDocs to modernize quality document management. Vault QualityDocs enables Samsung...
View ArticleClik here to view.
Hyleukin-7 Selected as a Korea Drug Development Fund (KDDF) Project for...
ROCKVILLE, Md. Genexine, a clinical stage biotechnology company developing innovative biologics, and its spin-off company in the US, NeoImmuneTech, Inc. (NIT), today announced that Hyleukin-7, their...
View ArticleClik here to view.
Emmaus Life Sciences Announces the New England Journal of Medicine has...
TORRANCE, Calif. VIEW E-MEDIA KIT – Emmaus Life Sciences, Inc. (Emmaus) announced today that the New England Journal of Medicine (NEJM) has published the results of its 48-week phase 3 clinical...
View ArticleClik here to view.
New Phase 3 Data Show Investigational Subcutaneous Formulation of Vedolizumab...
OSAKA, Japan Takeda Pharmaceutical Company Limited [TSE:4502] (“Takeda”) today announced top-line results from the VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational...
View ArticleClik here to view.
エマウスライフサイエンス社、ニューイングランド・ジャーナル・オブ・メディシン誌が鎌状赤血球症の治療でEndari™（L-グルタミン経口粉末薬）を検討した第...
米カリフォルニア州トーランス市 （ビジネスワイヤ） — VIEW E-MEDIA KIT –...
View ArticleClik here to view.
22nd Century宣布可立即执行FDA的尼古丁削减规划
纽约州威廉姆斯维尔 (美国商业资讯) — 22nd Century Group, Inc. (NYSE American:XXII) 是一家植物生物技术公司，也是烟草减害和极低尼古丁烟草领域的领先者，公司昨天回应了美国食品药品管理局(FDA)的提议规定预先通知...
View ArticleClik here to view.
Gynesonics Names George Quinoy Vice President, Global Sales
REDWOOD CITY, Calif. Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for uterine fibroids, today announced that veteran medical device sales...
View ArticleClik here to view.
AVITA Medical Announces Expansion of Management Team to Support Planned U.S....
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical (ASX: AVH) (OTCQX: AVMXY) today announced that it expanded its management team in the commercial, legal and medical affairs functions to...
View ArticleClik here to view.
Dr. Reddy’s Announces the Launch of Esomeprazole Magnesium Delayed-Release...
HYDERABAD, India & PRINCETON, N.J. Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the...
View ArticleClik here to view.
Alpine Immune Sciences Completes Sale of S-Nitrosoglutathione Reductase...
SEATTLE & HANGZHOU, China Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative, protein-based immunotherapies to treat cancer,...
View ArticleClik here to view.
Emmaus Life Sciences宣布《新英格兰医学杂志》发表 Endari™（左旋谷氨酰胺口服粉剂）治疗镰状细胞病3期试验结果
加州托伦斯 (美国商业资讯) — 参阅电子媒体包 – Emmaus Life Sciences, Inc. (Emmaus)今天宣布，《新英格兰医学杂志》(NEJM)已发表该公司Endari™（左旋谷氨酰胺口服粉剂）48周3期临床试验的结果，2017年7月，FDA依据该试验核准Endari™用于减少成人和5岁及以上儿童镰状细胞病患者的急性并发症。...
View ArticleClik here to view.
22ndセンチュリーはFDAのニコチン低減計画が直ちに実行可能であると発表
米ニューヨーク州ウィリアムズビル （ビジネスワイヤ） — タバコの有害性低減と超低ニコチンタバコでリードする植物バイオテクノロジー企業の22ndセンチュリー・グループ（NYSE...
View ArticleClik here to view.
SanBio: Joint Research Agreement for SB623 Targeting Dementia
TOKYO SanBio Company Limited, a scientific leader in regenerative medicine for neurological disorders, today announced it has concluded an agreement with Keio University School of Medicine on joint...
View ArticleClik here to view.
AVITA Medical Announces Results of Extraordinary General Meeting
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical (ASX: AVH) (OTCQX: AVMXY), a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns,...
View ArticleClik here to view.
FDA核准首款用于脊柱椎体间融合的纳米技术Peek器械
新罕布什尔州纳舒厄 (美国商业资讯) — 医疗器械公司Vallum Corporation今天宣布，美国食品药品管理局(FDA)已核准一款聚醚醚酮(PEEK)脊柱椎体间融合器械，该器械采用Vallum专有和受专利保护的加速中性原子束(ANAB)技术绘制的PEEKplus®纳米纹理1表面。 PEEKplus®是首款也是唯一获得FDA核准的PEEK椎体间器械纳米纹理表面。...
View ArticleClik here to view.
Takeda Announces Phase 3 Trial of ALUNBRIG® (brigatinib) Met Primary Endpoint...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the global, randomized, Phase 3 ALTA-1L (ALK in Lung Cancer Trial of AP26113 in 1st Line)...
View Article